Current Genes Tested by the Silver PGx Oncology Microarray Panel
The Silver PGx Oncology Panel analyzes germline variants across critical pharmacogenes. This list reflects the current content of the panel and is subject to updates as new clinical evidence and consensus guidelines emerge. All genes evaluated possess established CPIC (Clinical Pharmacogenetics Implementation Consortium) guidelines or recognized clinical utility in oncology pharmacogenomics, with specific emphasis on variants that influence systemic chemotherapy metabolism and related therapeutics.
Gene Categories
Core Genes possess a direct, well-established impact on major systemic chemotherapy agents and carry the strongest clinical actionability for treatment and dosing decisions in oncology frameworks.
Supporting Genes provide valuable pharmacogenomic insights for supportive care medications, pain management, hypersensitivity risk pathways, and perioperative safety in cancer patients.
Core Genes with Direct Impact on Oncology Therapeutics
| Gene | Primary Clinical Relevance | Notes |
|---|---|---|
| DPYD | Fluoropyrimidine metabolism (5-FU, capecitabine) | Critical for reducing severe toxicity risk |
| UGT1A1 | Irinotecan metabolism | Guides dosing to minimize severe neutropenia and diarrhea |
| TPMT | Thiopurine metabolism (mercaptopurine, thioguanine) | Important in hematologic malignancies and supportive care |
| NUDT15 | Thiopurine metabolism | Complements TPMT testing for improved safety |
| CYP2D6 | Tamoxifen metabolism | Affects efficacy in hormone receptor-positive breast cancer |
Supporting Pharmacogenes Included in the Panel
| Gene | Primary Relevance | Notes |
|---|---|---|
| CYP2C19 | Metabolism of several supportive care medications | Affects dosing of certain antidepressants, PPIs, and other drugs used in oncology patients |
| CYP2C9 | Metabolism of select supportive and anti-inflammatory agents | Relevant for pain management and other supportive therapies |
| G6PD | Glucose-6-phosphate dehydrogenase deficiency screening | Important for safety with certain supportive medications |
| HLA-B | Drug hypersensitivity risk | Relevant for allopurinol and other agents used in oncology supportive care |
| HLA-A | Drug hypersensitivity risk | Included for comprehensive pharmacogenomic coverage |
| RYR1 | Malignant hyperthermia susceptibility | Relevant for anesthesia risk in surgical oncology settings |
Laboratory Platform & Interpretation Standards
Testing Infrastructure: The panel is executed utilizing the Applied Biosystems™ Axiom™ PangenomiX Plus Array on the high-throughput GeneTitan™ MC platform from Thermo Fisher Scientific.
Allele Coverage: Variant and allele coverage for each targeted gene strictly aligns with current CPIC recommendations and molecular pathology best practices.
Clinical Curation: Results are interpreted and reported in strict accordance with peer-reviewed CPIC guidelines and curated by the laboratory’s clinical advisory resources.
Notice: This registry reflects the specific genes evaluated as of the most recent laboratory panel validation. Silver Gene Laboratories continuously monitors emerging clinical data and guidelines; panel content is subject to modification as new pharmacogenomic evidence is established. For the most current variant lists or validation documentation, please contact our clinical operations team directly.